Drug Concentration Analysis System Market Report 2026

The drug concentration analysis system market size has grown strongly in recent years. It will grow from $2.46 billion in 2025 to $2.65 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to increasing chronic disease prevalence, rising healthcare expenditure, expanding pharmaceutical research, growing demand for therapeutic drug monitoring, and rising regulatory quality control requirements.

The drug concentration analysis system market size is expected to see strong growth in the next few years. It will grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing investments in healthcare infrastructure, growing demand for precise drug monitoring, expanding pharmaceutical and biotechnology sectors, rising adoption of personalized medicine, and increasing pharma R&D spending. Major trends in the forecast period include technological advancements in analytical instruments, growth of point-of-care drug concentration systems, integration of automation and high-throughput testing, adoption of advanced bioanalytics methods, and increase in regulatory compliance and quality-assurance testing.

The growing demand for personalized medicine is expected to drive the expansion of the drug concentration analysis system market in the coming years. Personalized medicine is a healthcare approach that customizes treatments for individual patients based on their genetic, environmental, and lifestyle characteristics to achieve better clinical outcomes. This demand is rising due to advances in genomic technologies that allow precise identification of genetic variations and the development of individualized therapies. Drug concentration analysis systems support personalized medicine by accurately measuring drug levels in individual patients, enabling customized dosing and optimized treatment plans. They enhance therapeutic effectiveness by reducing adverse effects and ensuring that patients receive the most appropriate and safe medication strategies. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, up from 12 approvals in 2022. Consequently, the increasing adoption of personalized medicine is fueling the growth of the drug concentration analysis system market.

Major companies operating in the drug concentration analysis system market are concentrating on the development of advanced solutions, including rapid on-site testing platforms, to improve treatment optimization, strengthen personalized care, and reduce the time and costs associated with conventional laboratory testing. Rapid on-site testing platforms are sophisticated diagnostic systems that allow immediate, quantitative measurement of drug concentrations within clinical environments. For example, in October 2023, ProciseDx Inc., a US-based in vitro diagnostics company, received de novo clearance from the U.S. Food and Drug Administration for therapeutic drug monitoring tests for adalimumab (Humira and the biosimilar Amgevita) and infliximab (Remicade and the biosimilars Inflectra and Renflexis). These assays, known as Procise ADL and Procise IFX, use time-resolved fluorescence resonance energy transfer immunoassay technology to measure drug levels in serum and deliver results in approximately five minutes, enabling near real-time clinical decision-making during patient visits. This launch underscores a notable transition toward point-of-care drug concentration analysis systems that combine quantitative accuracy with operational simplicity, supporting personalized dosing strategies for patients with conditions such as inflammatory bowel disease.

In June 2025, SVAR Life Science AB, a Sweden-based provider of clinical diagnostics and laboratory solutions, entered into a partnership with Lablytica Life Science Pvt. Ltd. to strengthen capabilities in drug concentration analysis systems for both research and clinical use. Through this collaboration, SVAR Life Science AB and Lablytica Life Science Pvt. Ltd. seek to integrate advanced analytical instrumentation with laboratory expertise to enhance pharmacokinetic testing, bioanalysis, and therapeutic monitoring processes. Lablytica Life Science Pvt. Ltd. is an India-based life sciences and analytical services company.

Major companies operating in the drug concentration analysis system market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Siemens Healthineers AG, Danaher Corporation, Agilent Technologies Inc., BioMérieux Inc., Sartorius AG, Shimadzu Corporation, PerkinElmer Inc., Bruker Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Tecan Group Ltd., Randox Laboratories Ltd., Analytik Jena GmbH & Co. KG, KNAUER Wissenschaftliche Geräte GmbH, Chromsystems Instruments & Chemicals GmbH, American Laboratory Products Company Ltd.

North America was the largest region in the drug concentration analysis system market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug concentration analysis system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug concentration analysis system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have influenced the drug concentration analysis system market by increasing the cost of importing high-precision analytical instruments and reagents, particularly affecting regions like north america, europe, and asia-pacific where demand for advanced laboratory equipment is high. laboratory instrument segments such as mass spectrometry and liquid chromatography systems face supply chain challenges, resulting in delayed deployments and increased operational costs. however, tariffs are also encouraging local manufacturing and innovation in analytical solutions, which may enhance domestic capabilities and reduce dependency on imports over time.

A drug concentration analysis system is an integrated analytical solution that brings together instruments, detection technologies, and data processing tools to precisely measure the levels of drugs and their metabolites in biological samples. It is designed to support therapeutic drug monitoring, optimize dosing decisions, ensure patient safety, and enhance overall treatment effectiveness.

The key product types of drug concentration analysis systems include liquid chromatography systems, mass-spectrometry systems, spectrophotometry systems, and immunoassays. Liquid chromatography systems are analytical instruments that separate, identify, and quantify compounds in liquid samples. Sample types include blood, plasma, serum, urine, tissue samples, saliva, cell cultures, cerebrospinal fluid, and more. Distribution channels include online and offline sales, direct supply, third-party distributors, and retail outlets. Applications include therapeutic drug monitoring, pharmaceutical R&D, clinical trials, and bioavailability or bioequivalence studies, used by hospitals, pharmaceutical companies, CROs, academic institutions, and home-care settings.

The drug concentration analysis system market consists of revenues earned by entities by providing services such as therapeutic drug monitoring, bioanalytical testing, pharmacokinetic analysis, assay development and validation, and clinical laboratory data interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug concentration analysis system market also includes sales of analytical instruments, drug concentration analyzers, assay kits and reagents, integrated software platforms, and sample preparation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.